• +1-646-491-9876
    • +91-20-67278686

    Search

    Cognitive Impairment Associated With Schizophrenia-Pipeline Review H2 2017

    Cognitive Impairment Associated With Schizophrenia-Pipeline Review H2 2017

    • Report Code ID: RW0001881451
    • Category Life Sciences
    • No. of Pages 104
    • Publication Month Jul-17
    • Publisher Name Global Markets Direct
    Cognitive Impairment Associated With Schizophrenia (CIAS)-Pipeline Review H2 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Cognitive Impairment Associated With Schizophrenia (CIAS)-Pipeline Review H2 2017 provides an overview of the Cognitive Impairment Associated With Schizophrenia (CIAS) (Central Nervous System) pipeline landscape.

    Cognitive functioning is moderately to severely impair in patients with schizophrenia. Symptoms include poor executive functioning inability to sustain attention and problems with working memory. Predisposing factors include family history age and autoimmune diseases. Treatment includes antipsychotic medications.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Cognitive Impairment Associated With Schizophrenia (CIAS)-Pipeline Review H2 2017 provides comprehensive information on the therapeutics under development for Cognitive Impairment Associated With Schizophrenia (CIAS) (Central Nervous System) complete with analysis by stage of development drug target mechanism of action (MoA) route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics its complete research and development history and latest news and press releases.

    The Cognitive Impairment Associated With Schizophrenia (CIAS) (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Cognitive Impairment Associated With Schizophrenia (CIAS) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes the molecules developed by Companies in Phase II Phase I Preclinical and Discovery stages are 6 12 16 and 2 respectively.

    Cognitive Impairment Associated With Schizophrenia (CIAS) (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases company/university websites clinical trial registries conferences SEC filings investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Cognitive Impairment Associated With Schizophrenia (CIAS) (Central Nervous System) .
    - The pipeline guide reviews pipeline therapeutics for Cognitive Impairment Associated With Schizophrenia (CIAS) (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise product description descriptive licensing and collaboration details R&D brief MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Cognitive Impairment Associated With Schizophrenia (CIAS) (Central Nervous System) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Cognitive Impairment Associated With Schizophrenia (CIAS) (Central Nervous System) therapeutics based on mechanism of action (MoA) drug target route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Cognitive Impairment Associated With Schizophrenia (CIAS) (Central Nervous System)

    Reasons to buy

    - Procure strategically important competitor information analysis and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Cognitive Impairment Associated With Schizophrenia (CIAS) (Central Nervous System) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Cognitive Impairment Associated With Schizophrenia (CIAS) (Central Nervous System) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Cognitive Impairment Associated With Schizophrenia (CIAS)-Overview
    Cognitive Impairment Associated With Schizophrenia (CIAS)-Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Products under Development by Companies
    Cognitive Impairment Associated With Schizophrenia (CIAS)-Therapeutics Assessment
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Cognitive Impairment Associated With Schizophrenia (CIAS)-Companies Involved in Therapeutics Development
    AbbVie Inc
    Amarantus Bioscience Holdings Inc
    Astellas Pharma Inc
    AstraZeneca Plc
    Bristol-Myers Squibb Company
    Coronis NeuroSciences Ltd
    Eli Lilly and Company
    F. Hoffmann-La Roche Ltd
    H. Lundbeck A/S
    Heptares Therapeutics Ltd
    Intra-Cellular Therapies Inc
    Iproteos SL
    Luc Therapeutics Inc
    Neuralstem Inc
    Pfizer Inc
    Sage Therapeutics Inc
    Saniona AB
    SK Biopharmaceuticals Co Ltd
    Spherium Biomed SL
    Suven Life Sciences Ltd
    Takeda Pharmaceutical Company Ltd
    Vanda Pharmaceuticals Inc
    Cognitive Impairment Associated With Schizophrenia (CIAS)-Drug Profiles
    A-431404-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    AN-761-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    AQW-051-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ASP-4345-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ASP-5736-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    AUT-1-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    AUT-6-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    AUT-9-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    AVL-3288-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    basmisanil-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    BMS-955829-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    CP-102-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    davunetide-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    eltoprazine-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    erteberel-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    HTL-9936-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    IC-041-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    IPR-19-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ITI-214-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    LSN-2814617-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    LUAF-64280-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    NSI-189-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    PF-03463275-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    PF-04958242-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    roflumilast-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    SGE-301-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    SKLA-4R-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Agonize Dopamine D1 Receptor for Cognitive Impairment Associated with Schizophrenia-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Agonize NMDA2B for Cognitive Impairment Associated with Schizophrenia-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    SP-14040-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    SUVND-4010-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    SUVNG-3031-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    TAK-041-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    TAK-058-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    TAK-831-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    VU-0467154-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Cognitive Impairment Associated With Schizophrenia (CIAS)-Dormant Projects
    Cognitive Impairment Associated With Schizophrenia (CIAS)-Discontinued Products
    Cognitive Impairment Associated With Schizophrenia (CIAS)-Product Development Milestones
    Featured News & Press Releases
    Feb 01 2015 ASCIL Biopharm cooperates in a Project awarded with a "RETOS-ColaboraciĆ³n" grant
    Jan 27 2015 Spark a new public-private project created to develop a drug to fight the cognitive impairment associated with schizophrenia
    Apr 17 2013 SK Biopharma Announces FDA's Authorization Of IND For SKL15508 For Treatment Of Cognitive Impairment Associated With Schizophrenia
    Feb 19 2013 Intra-Cellular Therapies Completes Phase I Single Rising Dose Trial Of Selective Phosphodiesterase 1 Inhibitor
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development for Cognitive Impairment Associated With Schizophrenia (CIAS) H2 2017
    Number of Products under Development by Companies H2 2017
    Number of Products under Development by Companies H2 2017 (Contd..1) H2 2017
    Products under Development by Companies H2 2017
    Products under Development by Companies H2 2017 (Contd..1) H2 2017
    Number of Products by Stage and Target H2 2017
    Number of Products by Stage and Mechanism of Action H2 2017
    Number of Products by Stage and Route of Administration H2 2017
    Number of Products by Stage and Molecule Type H2 2017
    Cognitive Impairment Associated With Schizophrenia (CIAS)-Pipeline by AbbVie Inc H2 2017
    Cognitive Impairment Associated With Schizophrenia (CIAS)-Pipeline by Amarantus Bioscience Holdings Inc H2 2017
    Cognitive Impairment Associated With Schizophrenia (CIAS)-Pipeline by Astellas Pharma Inc H2 2017
    Cognitive Impairment Associated With Schizophrenia (CIAS)-Pipeline by AstraZeneca Plc H2 2017
    Cognitive Impairment Associated With Schizophrenia (CIAS)-Pipeline by Bristol-Myers Squibb Company H2 2017
    Cognitive Impairment Associated With Schizophrenia (CIAS)-Pipeline by Coronis NeuroSciences Ltd H2 2017
    Cognitive Impairment Associated With Schizophrenia (CIAS)-Pipeline by Eli Lilly and Company H2 2017
    Cognitive Impairment Associated With Schizophrenia (CIAS)-Pipeline by F. Hoffmann-La Roche Ltd H2 2017
    Cognitive Impairment Associated With Schizophrenia (CIAS)-Pipeline by H. Lundbeck A/S H2 2017
    Cognitive Impairment Associated With Schizophrenia (CIAS)-Pipeline by Heptares Therapeutics Ltd H2 2017
    Cognitive Impairment Associated With Schizophrenia (CIAS)-Pipeline by Intra-Cellular Therapies Inc H2 2017
    Cognitive Impairment Associated With Schizophrenia (CIAS)-Pipeline by Iproteos SL H2 2017
    Cognitive Impairment Associated With Schizophrenia (CIAS)-Pipeline by Luc Therapeutics Inc H2 2017
    Cognitive Impairment Associated With Schizophrenia (CIAS)-Pipeline by Neuralstem Inc H2 2017
    Cognitive Impairment Associated With Schizophrenia (CIAS)-Pipeline by Pfizer Inc H2 2017
    Cognitive Impairment Associated With Schizophrenia (CIAS)-Pipeline by Sage Therapeutics Inc H2 2017
    Cognitive Impairment Associated With Schizophrenia (CIAS)-Pipeline by Saniona AB H2 2017
    Cognitive Impairment Associated With Schizophrenia (CIAS)-Pipeline by SK Biopharmaceuticals Co Ltd H2 2017
    Cognitive Impairment Associated With Schizophrenia (CIAS)-Pipeline by Spherium Biomed SL H2 2017
    Cognitive Impairment Associated With Schizophrenia (CIAS)-Pipeline by Suven Life Sciences Ltd H2 2017
    Cognitive Impairment Associated With Schizophrenia (CIAS)-Pipeline by Takeda Pharmaceutical Company Ltd H2 2017
    Cognitive Impairment Associated With Schizophrenia (CIAS)-Pipeline by Vanda Pharmaceuticals Inc H2 2017
    Cognitive Impairment Associated With Schizophrenia (CIAS)-Dormant Projects H2 2017
    Cognitive Impairment Associated With Schizophrenia (CIAS)-Dormant Projects H2 2017 (Contd..1) H2 2017
    Cognitive Impairment Associated With Schizophrenia (CIAS)-Discontinued Products H2 2017

    List of Figures

    Number of Products under Development for Cognitive Impairment Associated With Schizophrenia (CIAS) H2 2017
    Number of Products under Development by Companies H2 2017
    Number of Products by Top 10 Targets H2 2017
    Number of Products by Stage and Top 10 Targets H2 2017
    Number of Products by Top 10 Mechanism of Actions H2 2017
    Number of Products by Stage and Top 10 Mechanism of Actions H2 2017
    Number of Products by Top 10 Routes of Administration H2 2017
    Number of Products by Stage and Top 10 Routes of Administration H2 2017
    Number of Products by Molecule Types H2 2017
    Number of Products by Stage and Molecule Types H2 2017
    AbbVie Inc
    Amarantus Bioscience Holdings Inc
    Astellas Pharma Inc
    AstraZeneca Plc
    Bristol-Myers Squibb Company
    Coronis NeuroSciences Ltd
    Eli Lilly and Company
    F. Hoffmann-La Roche Ltd
    H. Lundbeck A/S
    Heptares Therapeutics Ltd
    Intra-Cellular Therapies Inc
    Iproteos SL
    Luc Therapeutics Inc
    Neuralstem Inc
    Pfizer Inc
    Sage Therapeutics Inc
    Saniona AB
    SK Biopharmaceuticals Co Ltd
    Spherium Biomed SL
    Suven Life Sciences Ltd
    Takeda Pharmaceutical Company Ltd
    Vanda Pharmaceuticals Inc

    Request for Sample

    Report Url https://www.reportsweb.com//cognitive-impairment-associated-with-schizophrenia-pipeline-review-h2-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url https://www.reportsweb.com//cognitive-impairment-associated-with-schizophrenia-pipeline-review-h2-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url https://www.reportsweb.com//cognitive-impairment-associated-with-schizophrenia-pipeline-review-h2-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments